User:Colin404/Sandbox

Colin404/Sandbox
Clinical data
ATC code	none;
Identifiers
	IUPAC name N-(2-diethylaminoethyl)-2-[2-[(4-fluorophenyl)methylsulfanyl]-4-oxo-6,7-dihydro-5H-cyclopenta[d]pyrimidin-1-yl]-N-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide;
CAS Number	356057-34-6;
PubChem CID	9939609;
Chemical and physical data
Formula	C36H38F4N4O2S
Molar mass	666.77 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Fc4ccc(cc4)CSc(nc1=O)n(c5c1CCC5)CC(=O)N(CCN(CC)CC)Cc(cc3)ccc3-c(cc2)ccc2C(F)(F)F;

Darapladib is a drug used to inhibit lipoprotein-associated phospholipase A2 (lp-PLA2).

As of March 2008^[update], it is being studied as a possible add-on treatment for atherosclerosis.^[1]^[2]^[3]^[4]

References

^ Serruys, PW (2008). "Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque". Circulation. 118 (11): 1172–1182. doi:10.1161/CIRCULATIONAHA.108.771899. PMID 18765397. S2CID 9885557. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
^ Mohler, ER 3rd (2008). "The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study". Journal of the American College of Cardiology. 51 (17): 1632–41. doi:10.1016/j.jacc.2007.11.079. PMID 18436114. {{cite journal}}: More than one of |author= and |last= specified (help); Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)CS1 maint: numeric names: authors list (link)
^ Mohler, ER 3rd (2008). "Treating Residual Cardiovascular RiskWill Lipoprotein-Associated Phospholipase A2 Inhibition Live Up to Its Promise?". J Am Coll Cardiol. 51 (17): 1642–1644. doi:10.1016/j.jacc.2008.02.025. PMID 18436115. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)CS1 maint: numeric names: authors list (link)
^ Wilensky, RL (2008). "Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development". Nat Med. 14 (1015–1016): 1059–66. doi:10.1038/nm.1870. PMC 2885134. PMID 18806801. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)

External links

Commercial prospects of Darapladib

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[1] Serruys, PW (2008). "Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque". Circulation. 118 (11): 1172–1182. doi:10.1161/CIRCULATIONAHA.108.771899. PMID 18765397. S2CID 9885557. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)

[2] Mohler, ER 3rd (2008). "The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study". Journal of the American College of Cardiology. 51 (17): 1632–41. doi:10.1016/j.jacc.2007.11.079. PMID 18436114. {{cite journal}}: More than one of |author= and |last= specified (help); Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)CS1 maint: numeric names: authors list (link)

[3] Mohler, ER 3rd (2008). "Treating Residual Cardiovascular RiskWill Lipoprotein-Associated Phospholipase A2 Inhibition Live Up to Its Promise?". J Am Coll Cardiol. 51 (17): 1642–1644. doi:10.1016/j.jacc.2008.02.025. PMID 18436115. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)CS1 maint: numeric names: authors list (link)

[4] Wilensky, RL (2008). "Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development". Nat Med. 14 (1015–1016): 1059–66. doi:10.1038/nm.1870. PMC 2885134. PMID 18806801. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)

[1]

[2]

[3]

[4]